Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL.
ENCORE 601: ENT in combination with PEMBRO in Advanced Melanoma Patients
